Here are relevant reports on : lung-cancer-therapeutics-market
-
RNAI Technology Market- by Application (Research, Therapeutics) - Global Forecasts to 2019
The report presents the latest advances in RNAi technologies and their clinical implication as a therapeutic platform. It charts the current trends in RNAi therapeutics, and analyzes the opportunities and challenges faced by the RNAi companies. The focus will be on the clinical needs, patented technologies and the competitive landscape across geographies.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2030
The global Tissue Diagnostics market, valued at USD 6.19 billion in 2024, stood at USD 6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of USD10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Endoscopic Submucosal Dissection/ESD Market by Product (Gastroscopes & Endoscopes, Injection Agent, Tissue Retractor), Indication (Stomach Cancer, Colon Cancer), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center) - Global Forecast to 2030
The global endoscopic submucosal dissection market, valued at US$0.46 billion in 2024, stood at US$0.50 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$0.75 billion by the end of the period. The increasing adoption of endoscopic submucosal dissection (ESD) in Western countries is becoming a significant growth driver for the global ESD market.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Stomach Cancer Treatment Market by Treatment, Type (Chemotherapy, Immunotherapy), Disease Indication (Gastric Cancer), Route of Administration, Drug Class (PD-1/PD-L1 inhibitors, HER2 antagonists), Distribution Channel - Global Forecast to 2027
The global stomach cancer treatment market is projected to reach USD 8 billion by 2027 from USD 4 Billion in 2022, at a CAGR of 14% during the forecast period
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Forecast to 2024
The Cancer Registry Software Market is projected to reach USD 91 million by 2024, at a CAGR of 10.4%. Factors such as the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market. However, factors such as privacy and data security-related concerns are expected to restrain the growth of this market to a certain extent.Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US).
- Published: March 2019
- Price: $ 11000
- TOC Available:
-
Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035
The global Next-generation drug conjugates (NDCs) market is projected to reach USD 42.55 billion by 2035, growing at a CAGR of 11.7% during the forecast period (2026–2035). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: April 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
